Prenatal Diagnosis of 17p11.2 Copy Number Abnormalities Associated With Smith–Magenis and Potocki–Lupski Syndromes in Fetuses

Meiying Cai¹, Xianguo Fu², Liangpu Xu¹*, Na Lin¹* and Hailong Huang¹*

¹Medical Genetic Diagnosis and Therapy Center, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fujian Key Laboratory for Prenatal Diagnosis and Birth Defect, Fuzhou, China, ²Department of Prenatal Diagnosis, Ningde Municipal Hospital, Ningde Normal University, Ningde, China

Smith-Magenis syndrome and Potocki-Lupski syndrome are rare autosomal dominant diseases. Although clinical phenotypes of adults and children have been reported, fetal ultrasonic phenotypes are rarely reported. A retrospective analysis of 6,200 pregnant women who received invasive prenatal diagnosis at Fujian Provincial Maternal and Child Health Hospital between October 2016 and January 2021 was performed. Amniotic fluid or umbilical cord blood was extracted for karyotyping and single nucleotide polymorphism array analysis. Single nucleotide polymorphism array analysis revealed six fetuses with copy number variant changes in the 17p11.2 region. Among them, one had a copy number variant microdeletion in the 17p11.2 region, which was pathogenically analyzed and diagnosed as Smith-Magenis syndrome. Five fetuses had copy number variant microduplications in the 17p11.2 region, which were pathogenically analyzed and diagnosed as Potocki-Lupski syndrome. The prenatal ultrasound phenotypes of the six fetuses were varied. The parents of two fetuses with Potocki-Lupski syndrome refused verification. Smith-Magenis syndrome in one fetus and Potocki-Lupski in another were confirmed as de novo. Potocki-Lupski syndrome in two fetuses was confirmed to be from maternal inheritance. The prenatal ultrasound phenotypes of Smith-Magenis syndrome and Potocki-Lupski syndrome in fetuses vary; single nucleotide polymorphism array analysis is a powerful diagnostic tool for these diseases. The ultrasonic phenotypes of these cases may enrich the clinical database.

Keywords: smith-magenis syndrome, potocki-lupski syndrome, rare autosomal dominant, fetuses, copy number variant, SNP-array

1 INTRODUCTION

The gene density of chromosome 17 is the second-highest in the human genome, and it contains a large number of chromosome deletion and duplication pathogenic regions (Zody et al., 2006; Goldenberg, 2018). It has several dose-sensitive genes, such as PMP22 (Gillentine et al., 2018), PAFAH1B1 (Chen et al., 2018), YWHAE (Mignon-Ravix et al., 2010), RAI1 (Leviglio et al., 2016), and NF1 (Margraf et al., 2019), which are involved in multiple genetic diseases (Shchelochkov et al., 2010). Smith-Magenis syndrome (SMS) and Potocki-Lupski syndrome (PTLS) result from microdeletion and microduplication, respectively, occurring at the same location in the 17p11.2 region.
region, resulting in changes in the dose of sensitive genes and leading to two different syndromes (Heck et al., 2012; Twentyman, 2015).

SMS was first reported by Smith and colleagues in 1982 (Smith, 1982). It has an incidence of approximately 1:25,000 and is mostly sporadic. Currently, more than 100 cases have been reported worldwide, with affected individuals ranging in age from 1 month to 72 years (Edelman et al., 2007; Brendel et al., 2013). SMS is attributable to a 17p11.2 microdeletion. The main clinical manifestations in patients with SMS include mild to moderate intellectual impairment, cognitive impairment, distinct facial features (broad, square face, deep-set eyes, full cheeks, prominent jaw, flat nose, and downturned corners of the mouth), behavioral abnormalities, self-injurious behavior, and sleep disorders (Gouard et al., 2020). PTLS was first reported by Potocki and Lupski in 2000 (Potocki et al., 2007), and has an incidence of approximately 1:25,000 (Shuib et al., 2017). However, at present, less than 50 PTLS patients have been reported worldwide (Carter RD et al., 2013). PTLS is due to a 17p11.2 microduplication (Joseph et al., 2015). The main clinical manifestations in patients with PTLS include mild to moderate intellectual disability, short stature, inattention, autism, hyperactivity, triangular face, high zygomatic arch, frontal eminences, palatal dysplasia, and abnormal heart development (Twentyman, 2015).

SMS and PTLS are rare autosomal dominant diseases. Currently, clinical phenotypes of adults and children have been reported, while fetal ultrasonic phenotypes are rarely reported. In order to improve the understanding, diagnosis, and monitoring of these two rare genetic diseases in prenatal diagnosis, we retrospectively analyzed the ultrasonic phenotype and genetic results of one fetus with SMS and five fetuses with PTLS between October 2016 and January 2021 at the Fujian Provincial Maternal and Child Health Hospital.

2 MATERIALS AND METHODS

2.1 Study Participants and Samples
A retrospective analysis of 6,200 pregnant women who received invasive prenatal diagnosis in the Fujian Provincial Maternal and Child Health Hospital from October 2016 to January 2021 was performed. The mean age of the pregnant women was 28.4 years (range, 17–46 years) and mean gestational age was 24.2 weeks (range, 16–38 weeks). Amniocentesis or umbilical cord blood puncture was performed according to the pregnant woman’s gestational age. Under the guidance of ultrasound, 25–30 ml of amniotic fluid was extracted from pregnant women with a gestational age of less than 28 weeks, of which 20 ml was used for chromosome karyotype analysis, and the remaining 5–10 ml was used for single nucleotide polymorphism array (SNP-array). For pregnant women over 28 weeks of gestation, 3 ml of umbilical cord blood was extracted under ultrasound guidance, of which 1.5 ml was used for chromosome karyotype analysis and 1.5 ml for SNP-array. All pregnant women received genetic counseling and signed informed consent forms prior to the invasive diagnostic procedures. This study was approved by the Medical Ethics Committee of the Fujian Provincial Maternal and Child Health Hospital (2014042) and was conducted in accordance with the Declaration of Helsinki.

2.2 Karyotype Analysis
Samples of amniotic fluid or umbilical cord blood were inoculated in 1,640 culture mediums (Hangzhou Bosheng Biotechnology, Hangzhou, China). The cord blood samples were cultured for 3 days, and the cells were harvested. The amniotic fluid samples were cultured for 8 days, and the cell morphology and fluid change were observed. Colchicine was added to the cells with good growth morphology in the growth peak period to make the cells undergo the metaphase of mitosis. Thereafter, the cells were harvested. Finally, Giemsa dye banding was conducted, the karyotype was collected by GSL-120 automatic chromosome scanning platform, and the karyotype was calculated and analyzed. The karyotypes were named according to the 2016 edition of the International System for Human Cytogenomic Nomenclature (ISCN), 40 karyotypes were counted for each case, and 5 were analyzed. To account for abnormalities, double karyotype counting and analysis were performed.

2.3 Single Nucleotide Polymorphism Array
DNA digestion, PCR, PCR purification, fragmentation, labeling, hybridization, washing, staining, and scanning were performed according to the standard operating procedure of Affymetrix CytoScan 750K GeneChip (Affymetrix, CA, United States). After scanning, CEL files were created to obtain the fluorescence intensity data. The Chromosome Analysis Suite (ChAS) v3.2 was used to perform a single sample analysis which compared the data in a CEL file to a previously created reference file to find genomic abnormalities. The SNP-array results were further analyzed in combination with relevant databases to determine the properties of the copy number variations (CNVs). The databases included the International Public DGV Benign Variation Database, Database of Genomic Variation (DGV), Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources, Online Human Mendelian Genetic database, OMIM, the Cytogenomics Array Group CNV Database, NCBI, and PubMed. According to the guidelines of medical genetics in the United States (Riggs et al., 2020), CNVs are classified into pathogenic variants, possibly pathogenic variants, variants of uncertain clinical significance (VUS), possibly benign variants, and benign variants. In the fetuses with VUS, peripheral blood samples were collected from the parents for SNP-array, and family analysis was conducted to determine the exact classification of the CNV.

3 RESULTS

3.1 Prenatal Ultrasound Characteristics of Fetuses
The ultrasound phenotype of fetus E3640 at 34 weeks of gestation was cardiac malformation, hyperhydramnios, and minor ultrasonographic markers. The ultrasound phenotype of fetus P3350 at 25 weeks of gestation was cardiac malformation. The
ultrasound of P9874 at 24 weeks of gestation showed only minor ultrasonographic markers. The ultrasound phenotype of fetus R425 at 20 weeks of gestation was normal, but the mother displayed intellectual disability. The fetuses G8354 and P587 were from the same mother, and the mother displayed intellectual disability. G8354 was the first fetus in 2016 whose ultrasound phenotype showed cardiac malformation at 25 weeks of gestation. P587 was the second fetus in 2020 whose ultrasonic phenotype was normal at 22 weeks of gestation. The clinical information and prenatal ultrasound phenotypes of the six fetuses are shown in Table 1.

### 3.2 Karyotype Analysis

Results of the karyotype analysis for all six fetuses were normal.

### 3.3 SNP-Array

The results of SNP-array analysis in the 6,200 fetuses revealed six fetuses with a CNV in the 17p11.2 region (Table 2). Case E3640 showed 17p11.2 microdeletion, involving a fragment approximately 3.7 Mb in size and containing 38 OMIM genes, such as RAI1 (Figure 1). Five fetuses (G8354, P587, P3350, and R425) showed 17p11.2 microduplication. Fetuses G8354, P587, P3350, and P9874 had fragments of about 2.1–3.7 Mb size and contained 21–38 OMIM genes (including RAI1).

### 3.4 Detection of Parent-of-Origin

The parents of two fetuses (P9874 and R425) refused detection of parent-of-origin effects, while the parents of the remaining four fetuses agreed. In case E3640, the microdeletion of CNVs in 17p11.2 was de novo. The microduplication of CNVs in 17p11.2 in case P3350 was de novo. However, the fetuses G8354 and P587 inherited the CNVs from their mother (Figure 2). G8354 and P587 are

### Table 1 | Clinical information and prenatal ultrasound phenotypes of the six fetuses.

| Case  | Gestation | Specimen type | Mother phenotype | Father phenotype | Prenatal ultrasound characteristics |
|-------|-----------|---------------|------------------|------------------|-----------------------------------|
| E3640 | 34        | umbilical cord blood | normal           | normal           | VSD, minimal pulmonary valve regurgitation, persistent left superior vena cava, absence of nasal bone, thickened skin on the back of head and neck. |
| G8354 | 25        | amniotic fluid   | intellectual disability | normal           | VSD, severe tricuspid regurgitation, pericardial effusion, FGR |
| P587 | 22        | amniotic fluid   | intellectual disability | normal           | Strong echo points in left and right ventricular chordal tendiniae, and a small amount of tricuspid regurgitation |
| P9874 | 24        | amniotic fluid   | normal           | normal           | Right aortic arch with mirrored branches, right ductus arteriosus |
| P3350 | 25        | amniotic fluid   | normal           | normal           | |
| R425 | 20        | amniotic fluid   | normal           | normal           | |

FGR, fetal growth restriction; VSD, ventricular septal defect. The fetuses G8354 and P587 were from the same mother, and the mother displayed intellectual disability.

### Table 2 | Results of SNP-array in six fetuses.

| Case  | SNP-array | Size (Mb) | Disease | Inheritance |
|-------|-----------|-----------|---------|-------------|
| E3640 | arr[hg19] 17p11.2(16,727,490–20,433,723)x1 | 3.7 | SMS | de novo |
| G8354 | arr[hg19] 17p11.2(16,567,623–18,743,354)x3 | 2.1 | PTLS | Maternal |
| P587 | arr[hg19] 17p11.2(16,600,022–20,407,931)x3 | 3.7 | PTLS | Maternal |
| P9874 | arr[hg19] 17p11.2(16,600,022–18,746,988)x3 | 2.1 | PTLS | — |
| P3350 | arr[hg19] 17p11.2(16,615,982–18,922,171)x3 | 2.1 | PTLS | — |
| R425 | arr[hg19] 17p11.2(16,600,022–20,407,931)x3 | 3.7 | PTLS | de novo |

SMS, Smith-magenis syndrome; PTLS, Potocki-Lupski syndrome.

### Figure 1 | Chromosome 17p 11.2 imbalance detected by SNP-array. In fetus E3640, the SNP-array revealed that the microdeletion of the CNV in 17p11.2 involved a 3.7 Mb fragment and contained 38 OMIM genes (including RAI1). In fetuses G8354, P587, P9874, P3350, and R425, the SNP-array revealed that the microduplication of the CNV in 17p11.2 involved about 2.1–3.7 Mb fragment size and contained 21–38 OMIM genes (including RAI1).
from the same family, and their mothers display intellectual
disability. G8354, conceived in 2016, was the first child of the
mother with intellectual disability, and P587 was the second
child conceived in 2020.

3.5 Pathogenic Analysis
In fetus E3640, the SNP-array revealed that the microdeletion of
the CNV in 17p11.2 involved a 3.7 Mb fragment and contained 38
OMIM genes. According to the database and literature, this
segment contained a 17p11.2 recurrent region, including RAI1.
According to the ClinGen database, this region had
haploinsufficiency (score 3), and the loss of heterozygosity in
this region was associated with SMS, thus, the clinical signifi-
cance was pathogenic.

In fetuses G8354, P587, P9874, P3350, and R425, the SNP-array
revealed that the microduplication of the CNV in 17p11.2 involved
about 2.1–3.7 Mb fragment size and contained 21–38 OMIM
genes. According to the database and literature, this segment
contained a 17p11.2 recurrent region (including RAI1).
According to the ClinGen database, this region had a triple
dose sensitive effect, which may lead to PTLS, thus, the clinical
significance was pathogenic.

3.6 Pregnancy outcome
In all six cases the parents of the fetuses chose to terminate the
pregnancy after adequate genetic counseling to inform them of
the possible risks.

4 DISCUSSION
To date, over 100 cases of SMS have been reported worldwide.
The incidence of PTLS is rarer, with only over 50 cases reported,
and few clinical cases reported in Asia. Both SMS and PTLS are
characterized by developmental delays, language disorders, and
intellectual disability. SMS also manifests as self-injurious
behavior, irritability, sleep disorders, obesity, behavioral
abnormalities, and distinct facial and skeletal deformities
(Marta et al., 2012; Poisson A et al., 2015; Gupta et al., 2016;
Spruyt et al., 2016). SMS is rarely diagnosed in childhood, and its
clinical symptoms become more obvious with age (Lee et al.,
2012; Gouard et al., 2020). The manifestations of PTLS are less
serious than those of SMS. PTLS is characterized by hypotonia,
autism, structural cardiovascular abnormalities, and apnea (Lee
et al., 2012). These clinical phenotypes are observed in both
children and adults.

Currently, there are few reported cases of fetuses with SMS or
PTLS with ultrasound phenotypes. This paper summarized the
reported cases of ultrasound phenotypes in fetuses with SMS and
PTLS (Tables 3, 4). The ultrasound phenotype of one fetus with
SMS in this study was cardiac malformation and polyhydramnios,
which was consistent with the fetal ultrasound phenotype reported in the literature (Table 3). Congenital heart defects, including ventricular septal defects, have been described in 30% of SMS individuals. Prenatal ultrasound showed that a fetus with cardiac malformation may have cardiac defects after birth. However, since the families
decided to terminate the pregnancies, we were not able to
track whether the fetuses were characterized with cardiac
defects and other phenotypes.

Of the other five fetuses with PTLS, two had cardiac
malformations, two had normal ultrasound phenotypes, and
one had minor ultrasonographic markers. These are
inconsistent with the literature (Table 4). In this study, two
fetuses with PTLS were the first and second fetuses of the same
mother with intellectual disability. The ultrasound phenotype
of the first fetus was cardiac malformation and fetal growth
restriction, while the ultrasound phenotype of the second was
normal. Based on these reports and our cases, the prenatal
ultrasound findings of PTLS are not specific and may be
completely normal. The most frequent ultrasound findings
in fetuses are cardiovascular anomalies and are reported in
about 40% of individuals with PTLS. The ultrasonic
phenotypes of these cases may enrich the clinical database.
Clinical phenotypes of SMS and PTLS are complex and diverse,
requiring a large amount of sample data and more in-depth
clinical studies.

With the development of molecular diagnostic technology,
an increasing number of microdeletion and microduplication
syndromes have been found (Wou et al., 2016); in the present
study, SMS and PTLS were two such syndromes. Chromosome
cytogenetic analysis is the most classical and common detection
method, but the resolution is low, and it can generally only
detect duplication, deletion, translocation, and other structural
abnormalities larger than 10 Mb. The karyotype analysis of six
fetuses in this study was normal. Currently, cases of SMS and
PTLS are detected using chromosomal microarray analysis (CMA). CMA is divided into two categories (Brady and
Vermeesch, 2012), array-based comparative genomic
hybridization (array-CGH) and single-nucleotide
polymorphism arrays (SNP-array) (Xiang et al., 2020). SNP-
array can not only detect the CNV, but it can also detect
abnormalities such as uniparental disomy, low level chimera,
and triploidy (Zhang Y. et al., 2020). In this study, the SNP-
array showed that one case of SMS and one case of PTLS had a
3.7 Mb microdeletion and a 3.7 Mb microduplication,
respectively, in the same location. In general, cases with
microduplications have milder clinical manifestations than
cases with microdeletions. In this study, one case of SMS
with a 3.7 Mb microdeletion had a severe ultrasonic
phenotype, while one case of PTLS with a 3.7 Mb
microdeletion had a normal ultrasonic phenotype. A
2.1 Mb microduplication was observed in four cases of
PTLS. The region of genetic variation in these all cases
contained the RAI1 gene. RAI 1 is a transcription factor
involved in cell growth and cell cycle regulation, bone and
bone development, lipid and glucose metabolism, embryonic
nerual development and neuronal differentiation, behavioral
function, and circadian activity (Vilhais-Neto et al., 2010;
Fragoso et al., 2015; Garay et al., 2020). Copy number loss
of RAI1 results in SMS (Falco et al., 2017), and copy number
gain of RAI1 results in PTLS (Chen et al., 2016).

In this study, three of the five fetuses with PTLS had mothers with
intellectual disability. The SNP-array of one fetus with SMS and one fetus with
PTLS identified the origins as de novo by detecting the parent-of-
origin. SMS and PTLS can be inherited in an autosomal dominant
manner, however most are de novo, and very few patients inherit the
aforementioned syndromes from their parents. For de novo CNV-
induced SMS and PTLS, the risk of recurrence was less than 1%, but
prenatal diagnosis was still required for a second pregnancy.
Currently, there are few reports of births in patients with SMS
and PTLS (Acquaviva et al.; Magoulas et al., 2014). In the case of the
mother with PTLS reported in this paper, the risk of offspring
recurrence was 50%. Considering that both the first and second
children had PTLS, it is suggested that the patient should have
prenatal diagnosis or undergo third generation in vitro fertilization
to ensure healthy children.

The prenatal ultrasound phenotype of 17p11.2 copy
number abnormalities associated with Smith–Magenis
syndrome and Potocki–Lupski syndrome in fetuses displays
heterogeneity. There are many challenges in fetal ultrasound
diagnosis, which can be specifically divided as follows: 1) many
structural abnormalities may be discovered in the
middle and late stages; 2) some phenotypes, such as
intellectual disability, cannot be expressed during the fetal
period; 3) reduced fetal movement and other functional
phenotypes have great limitations; 4) the prenatal
phenotypes of chromosomal and other genetic disorders
were heterogeneous and nonspecific in clinical descriptions,
even in fetuses. We believe that fetal magnetic resonance
imaging plays a good auxiliary role in the detection of
nervous system abnormalities (Di Mascio et al., 2021;
Papaioannou et al., 2021).

In conclusion, the 17p11.2 copy number abnormality has
variable expressivity with the phenotypes being milder in some
patients. SNP-array analysis is used in the prenatal diagnosis
of fetal ultrasound abnormalities and pregnant women with
intellectual disability. In the future, detailed molecular genetic
testing and prenatal ultrasonographic analysis of a higher
number of cases of SMS and PTLS in fetuses will aid in the

---

**TABLE 3** | Reports of ultrasound phenotypes in fetuses with SMS.

| References | Ultrasound phenotypes in fetuses |
|------------|---------------------------------|
| Thomas et al. (2000) | Short heads, short bones and heart malformations |
| Fan and Farrell (2010) | Duplicated right ureter |
| Zhou et al. (2015) | Ventricular septal defect, pulmonary stenosis, fetal growth restriction |
| Le et al. (2016) | Increased nuchal translucency, mild lateral ventriculomegaly, and congenital heart defects |
| Zhang et al. (2020a) | Polytrophy, ventriculomegaly and external genital defects |

**TABLE 4** | Reports of ultrasound phenotypes in fetuses with PTLS.

| References | Ultrasound phenotypes in fetuses |
|------------|---------------------------------|
| Popowski et al. (2012) | Asymmetric ears |
| Bravo et al. (2013) | Hypoplastic left heart and aberrant right subclavian artery |
| Dhanaraj et al. (2015) | Bilateral clubfoot |
| Yusupov et al. (2011) | Micrognathia, increased nuchal translucency, intrauterine growth retardation, and a two-vessel cord |
identification of SMS and PTLS in fetuses and in the accurate localization of other related genes.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Medical Ethics Committee of Fujian Provincial Maternal and Child Health Hospital (2014042). The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

LX: Designed the study. MC: Wrote the manuscript. HH revised the article. XF performed the statistical analyses. NL interpreted the data.

**FUNDING**

The present study was supported by the Fujian Provincial Natural Science Foundation, 2017J01238.

**REFERENCES**

Acquaviva, F., Sana, M. E., Della Monica, M., Pinelli, M., Postorivo, D., Fontana, P., et al. (2017). First Evidence of Smith-Magenis Syndrome in Mother and Daughter Due to a Novel RAI Mutation. *Am. J. Med. Genet. A* 173 (1), 231–238. doi:10.1002/ajmg.a.37989

Alaimo, J. T., MullegamaSureni, S. V., Thomas, M. A., ElseaSarah, S. H., and Elsea, S. H. (2015). Copy Number Loss Upstream of RAI1 Uncovers Gene Expression Regulatory Region that May Impact Potocki-Lupski Syndrome Diagnosis. *Mol. Cytogenet.* 8, 75–80. doi:10.1186/s13039-015-0179-7

Brady, P. D., and Vermeesch, J. R. (2012). Genomic Microarrays: a Technology Overview. *Prenat Diagn.* 32 (4), 336–343. doi:10.1002/pd.2933

Bravo, C., Gámez, F., Pérez, R., Aguarón, Á., and De León-Luis, J. (2013). Prenatal Diagnosis of Potocki-Lupski Syndrome in a Fetus with Hypoplastic Left Heart and Aberrant Right Subclavian Artery. *J. Perinatol.* 33 (5), 394–396. doi:10.1038/jp.2012.77

Cai et al. Prenatal Smith-Magenis and Potocki-Lupski Syndromes

Carter, R. D., Raia, M., Ewing-Cobbs, L., Gambello, M., Hashmi, S. S., Peterson, S. K., et al. (2013). Stress and Well-Being Among Parents of Children with Potocki-Lupski Syndrome. *Jrnl of Gene Currn* 22 (5), 633–642. doi:10.1007/s10897-013-9602-6

Chen, C.-P., Ko, T.-M., Wang, L.-K., Chern, S.-R., Wu, P.-S., Chen, S.-W., et al. (2018). Prenatal Diagnosis of a 0.7-Mb 17p13.3 Microdeletion Encompassing YWHAE and CRK but Not PAFAH1B1 in a Fetus without Ultrasound Abnormalities. *Taiwanese J. Obstet. Gynecol.* 57 (1), 128–132. doi:10.1016/j.tjog.2017.12.022

Chen, L., Tao, Y., Song, F., Yuan, X., Wang, J., and Saffen, D. (2016). Evidence for Genetic Regulation of mRNA Expression of the Dosage-Sensitive Gene Retinoic Acid Induced-1 (RAI1) in Human Brain. *Sci. Rep.* 6, 19010. doi:10.1038/srep19010

De Leersnyder, H., King, K. A., Zalewska, C. K., Finucane, B. M., Introne, W., Brewer, C. C., et al. (2013). Smith-Magenis Syndrome. *Handb Clin. Neurol.* 111, 295–296. doi:10.1016/B978-0-444-52891-9-00034-8

Dhanaraj, D., Chu, A., Pappas, J. G., Moran, E., and Lehman, W. B. (2015). Potocki-Lupski Syndrome in Conjunction with Bilateral Clubfoot. *Am. J. Med. Genet. A* 167 (18), 4051–4055. doi:10.1002/ajmg.a.36501

Di Mascio, D., Khalil, A., Pilu, G., Rizzo, G., Caulo, M., Liberati, M., et al. (2021). Role of Prenatal Magnetic Resonance Imaging in Fetuses with Increased Nuchal Translucency, Mild Lateral Ventriculomegaly, and Congenital Heart Defects. *Taiwanese J. Obstet. Gynecol.* 55 (6), 886–890. doi:10.1016/j.tjog.2015.07.007

Fan, Y.-S., and Farrell, S. A. (1994). Prenatal Diagnosis of Interstitial Deletion of 17p11.2p11.2 (Smith-Magenis Syndrome). *Am. J. Med. Genet.* 49 (2), 253–254. doi:10.1002/ajmg.a.37989

Fragoso, Y. D., Stoney, P. N., Shearer, K. D., Sementilli, A., Nanescu, S. E., Sementilli, P., et al. (2015). Expression in the Human Brain of Retinoic Acid Induced 1, a Protein Associated with Neurobehavioural Disorders. *Brain Struct. Funct.* 220 (2), 1195–1203. doi:10.1007/s00429-014-0712-1

Garay, P. M., Chen, A., Tsukahara, T., Rodriguez Diaz, J. C., Kohen, R., Althaus, J. C., et al. (2020). RAI1 Regulates Activity-dependent Nascent Transcription and Synaptic Scaling. *Cel Rep.* 32 (6), 108002. doi:10.1016/j.celrep.2020.108002

Gillentine, M. A., Lupo, P. J., Stankiewicz, P., and Scharf, C. P. (2018). An Estimation of the Prevalence of Genomic Disorders Using Chromosomal Microarray Data. *J. Hum. Genet.* 63 (7), 795–801. doi:10.1038/s10038-018-0451-x

Goldenberg, P. (2018). An Update on Common Chromosome Microdeletion and Microduplication Syndromes. *Pediatr. Ann.* 47 (5), e196–e203. doi:10.3928/19382359-20180419-01

Gupta, R., Gupta, N., Namppoththi, S., Mandal, K., Kishore, Y., Sharma, P., et al. (2016). Smith-Magenis Syndrome: Face Speaks. *Indian J. Pediatr.* 83 (6), 589–593. doi:10.1007/s12098-015-1940-y

Heck, D. H., Gu, W., Cao, Y., Qi, S., Lacaria, M., and Lupski, J. R. (2012). Opposing Phenotypes in Mice with Smith-Magenis Deletion and Potocki-Lupski Duplication Syndromes Suggest Gene Dosage Effects on Fluid Consumption Behavior. *Am. J. Med. Genet. A* 158A (11), 2807–2814. doi:10.1002/ajmg.a.35601

Lee, C. G., Park, S.-J., Yun, J.-N., Kim, S.-Y., and Sohn, Y. B. (2012). Reciprocal Deletion and Duplication of 17p11.2-11.2: Korean Patients with Smith-Magenis Syndrome and Potocki-Lupski Syndrome. *J. Korean Med. Sci.* 27 (12), 1586–1590. doi:10.3344/jkms.2012.27.12.1586

Lei, T.-Y., Li, R., Fu, F., Wan, J.-H., Zhang, Y.-L., Jing, X.-Y., et al. (2016). Prenatal Diagnosis of Smith-Magenis Syndrome in Two Fetuses with Increased Nuchal Translucency, Mild Lateral Ventriculomegaly, and Congenital Heart Defects. *Taiwanese J. Obstet. Gynecol.* 55 (6), 886–890. doi:10.1016/j.tjog.2015.07.007

Loviglio, M. N., Beck, C. R., White, J. J., Leelu, M., Hartl, T., Guex, N., et al. (2016). Identification of a RA11-Associated Disease Network through Integration of Exome Sequencing, Transcriptomics, and 3D Genomics. *Genome Med.* 8 (1), 105. doi:10.1186/s12935-016-0359-z

Magoulas, P. L., Liu, P., Gelovani, V., Soler-Alfonso, C., Kivuva, E. C., Lups, J. R., et al. (2014). Inherited dup(17)(p11.2p11.2): Expanding the Phenotype of the Potocki-Lupski Syndrome. *Am. J. Med. Genet. A* 164 (2), 500–504. doi:10.1002/ajmg.a.36287

Margraf, R. L., Vansant-Webb, C., Mao, R., Viskokich, D. H., Carey, J., Hanson, H., et al. (2019). NFI Somatic Mutation in Dysrophic Scoliosis. *J. Mol. Neurosci.* 68 (1), 11–18. doi:10.1007/s12031-019-01277-0

Mignon-Ravix, C., Cacciagli, P., El-Waly, B., Moncla, A., Milh, M., Girard, N., et al. (2010). Deletion of YWHAE in a Patient with Perveriventricular Heterotopias and Pronounced Corpus Callosum Hypoplasia. *J. Med. Genet.* 47 (2), 132–136. doi:10.1136/jmedgen.2009.069112
Neira-Fresneda, J., and Potocki, L. (2015). Neurodevelopmental Disorders Associated with Abnormal Gene Dosage: Smith-Magenis and Potocki-Lupski Syndromes. J. Pediatr. Genet. 04 (3), 159–167. doi:10.1055/s-0035-1564443

Novákova, M., Nevičmalová, S., Píhodrová, L., Sládek, M., and Sumová, A. (2012). Alteration of the Circadian Clock in Children with Smith-Magenis Syndrome. J. Clin. Endocrinol. Metab. 97 (2), E312–E318. doi:10.1210/jc.2011-2750

Papaioannou, G., Klein, W., Cassart, M., and Garel, C. (2021). Indications for Magnetic Resonance Imaging of the Fetal central Nervous System: Recommendations from the European Society of Paediatric Radiology Fetal Task Force. Pediatr. Radiol. 51 (11), 2105–2114. doi:10.1007/s00247-021-05104-w

Poisson, A., Nicolas, A., Cochat, P., Sanlaville, D., Rigard, C., de Leersnyder, H., et al. (2015). Behavioral Disturbance and Treatment Strategies in Smith-Magenis Syndrome. Orphanet J. Rare Dis. 10, 111. doi:10.1186/s13023-015-0330-x

Popowski, T., Molina-Gomes, D., Loeuillet, L., Boukobza, P., Roume, J., and Vialard, F. (2012). Prenatal Diagnosis of the Duplication 17p11.2 Associated with Potocki-Lupski Syndrome in a Foetus Presenting with Mildly Dysmorphic Features. Eur. J. Med. Genet. 55 (12), 723–726. doi:10.1016/j.ejmg.2012.08.008

Potocki, L., Bi, W., Treadwell-Deering, D., Carvalho, C. M. B., Eifert, A., Friedman, E. M., et al. (2007). Characterization of Potocki-Lupski Syndrome (dup(17)(p11.2p11.2)) and Delineation of a Dosage-Sensitive Critical Interval that Can Convey an Autism Phenotype. Am. J. Hum. Genet. 80 (4), 633–649. doi:10.1086/512864

Riggs, E. R., Andersen, E. F., Cherry, A. M., Kantarci, S., Kearney, H., Patel, A., et al. (2020). Technical Standards for the Interpretation and Reporting of Constitutional Copy-Number Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet. Med. 22 (2), 245–257. doi:10.1038/s41436-019-0686-8

Rive Le Gouard, N., Jacquinet, A., Ruaud, L., Deleersnyder, H., Ageorges, F., Gallard, J., et al. (2021). Smith-Magenis Syndrome: Clinical and Behavioral Characteristics in a Large Retrospective Cohort. Clin. Genet. 99, 519–528. doi:10.1111/cge.13906

Shchelochkov, O. A., Cheung, S. W., and Lupski, J. R. (2010). Genomic and Clinical Characteristics of Microduplications in Chromosome 17. Am. J. Med. Genet. 152A (5), 1101–1110. doi:10.1002/ajmg.a.33248

Shuib, S., Saaid, N. N., Zuria, Z., Ismail, J., and Abdul Latiff, Z. (2017). Duplication 17p11.2 (Potocki-Lupski Syndrome) in a Child with Developmental Delay. Malays J. Pathol. 39 (1), 77–81.

Smith, A. (1982). Deletion of the 17 Short Arm in 2 Patients with Facial Clefs. Am. J. Med. Genet. 34. doi:10.1111/j.1365-201x.04698.x

Spruyt, K., Braam, W., Smits, M., and Curfs, L. M. (2016). Sleep Complaints and the 24-h Melatonin Level in Individuals with Smith-Magenis Syndrome: Assessment for Effective Intervention. CNS Neuropsy. Ther. 22 (11), 928–935. doi:10.1111/cns.12653

Thomas, D. G., Jacques, S. M., Flore, L. A., Feldman, B., Evans, M. I., and Qureshi, F. (2000). Prenatal diagnosis of smith-magenis syndrome (del 17p11.2). Fetal Diagn. Ther. 15 (6), 335–337. doi:10.1159/000021032

Vilhais-Neto, G. C., Maruhashi, M., Smith, K. T., Vasseur-Cognet, M., Peterson, A. S., Workman, J. L., et al. (2010). Rere Controls Retinoic Acid Signalling and Somite Bilateral Symmetry. Nature 463 (7283), 953–957. doi:10.1038/nature08763

Wou, K., Levy, B., and Wapner, R. J. (2016). Chromosomal Microarrays for the Prenatal Detection of Microdeletions and Microduplications. Clin. Lab. Med. 36 (2), 261–276. doi:10.1016/j.cll.2016.01.017

Xiang, J., Ding, Y., Song, X., Mao, J., Liu, M., Liu, Y., et al. (2020). Clinical Utility of SNP Array Analysis in Prenatal Diagnosis: A Cohort Study of 5000 Pregnancies. Front. Genet. 11, 571219. doi:10.3389/fgene.2020.571219

Yusupov, R., Roberts, A. E., Lacro, R. V., Sandstrom, M., and Ligon, A. H. (2011). Potocki-Lupski Syndrome: An Inherited dup(17)(p11.2p11.2) with Hypoplastic Left Heart. Am. J. Med. Genet. 155 (2), 367–371. doi:10.1002/ajmg.a.33845

Zhang, P., Sun, Y., Tian, H., Rong, L., Wang, F., Yu, X., et al. (2020a). Prenatal Diagnosis and Neonatal Phenotype of a De Novo Microdeletion of 17p11.2p12 Associated with Smith–Magenis Syndrome and External Genital Defects. J. Genet. 99. doi:10.1007/s12041-020-01213-x

Zhang, Y., Zhong, M., and Zheng, D. (2020b). Chromosomal Mosaicism Detected by Karyotyping and Chromosomal Microarray Analysis in Prenatal Diagnosis. J. Cel. Mol. Med. 25 (1), 358–366. doi:10.1111/jcmm.16080

Zhou, Y., Xie, Y., Zhu, Y., Wu, J., Shang, M., Chen, B., et al. (2015). Smith-Magenis Syndrome and External Genital Defects. J. Cel. Mol. Med. 19 (10), 4375–4382. doi:10.1111/jcmm.13605

Zody, M. C., Garber, M., Adams, D. J., Sharpe, T., Harrow, J., Lupski, J. R., et al. (2006). DNA Sequence of Human Chromosome 17 and Analysis of Rearrangement in the Human Lineage. Nature 440 (7087), 1045–1049. doi:10.1038/nature04689

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Cai, Fu, Xu, Lin and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.